RotaTeq™, rotavirus vaccine, live, oral, pentavalent + Comparator: Placebo matching RotaTeq™

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rotavirus Infections

Conditions

Rotavirus Infections

Trial Timeline

Sep 1, 2002 → Jun 1, 2004

About RotaTeq™, rotavirus vaccine, live, oral, pentavalent + Comparator: Placebo matching RotaTeq™

RotaTeq™, rotavirus vaccine, live, oral, pentavalent + Comparator: Placebo matching RotaTeq™ is a phase 3 stage product being developed by Merck for Rotavirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00092443. Target conditions include Rotavirus Infections.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00092443Phase 3Completed